Diabetes 52:2731-2739, 2003
© 2003 by the American Diabetes Association, Inc.
Rapamycin Has a Deleterious Effect on MIN-6 Cells and Rat and Human Islets
Ewan Bell1,
Xiaopei Cao1,
Jacob A. Moibi1,
Scott R. Greene1,
Robert Young1,
Matteo Trucco1,
Zhiyong Gao1,
Franz M. Matschinsky2,
Shaoping Deng3,
James F. Markman3,
Ali Naji3, and
Bryan A. Wolf1
1 Department of Pathology and Laboratory Medicine, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania
2 Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
3 Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Rapamycin (sirolimus) is a macrolide fungicide with immunosuppressant properties that is used in human islet transplantation. Little is known about the effects of rapamycin on MIN-6 cells and islets. Rapamycin had a dose-dependent, time-dependent, and glucose-independent deleterious effect on MIN-6 cell viability. At day 1, using the MTT method, 0.01 nmol/l rapamycin reduced cell viability to 83 ± 6% of control (P < 0.05). Using the calcein AM method, at day 2, 10 nmol/l rapamycin caused a reduction in cell viability to 73 ± 5% of control (P < 0.001). Furthermore, 10 and 100 nmol/l rapamycin caused apoptosis in MIN-6 cells as assessed by the transferase-mediated dUTP nick-end labeling assay. Compared with control, there was a 3.1 ± 0.6-fold increase (P < 0.01) in apoptosis in MIN-6 cells treated with 10 nmol/l rapamycin. A supra-therapeutic rapamycin concentration of 100 nmol/l significantly impaired glucose- and carbachol-stimulated insulin secretion in rat islets and had a deleterious effect on the viability of rat and human islets, causing apoptosis of both - and ß-cells.
Address correspondence and reprint requests to Dr. Bryan A. Wolf, Department of Pathology and Laboratory Medicine, Childrens Hospital of Philadelphia, 5135 Main, 34th Street and Civic Center Blvd., Philadelphia, PA 19104-4399. E-mail: wolfb{at}mail.med.upenn.edu

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. Su, N. Zhang, J. He, S. Qu, S. Slusher, R. Bottino, S. Bertera, J. Bromberg, and H. H. Dong
Angiopoietin-1 Production in Islets Improves Islet Engraftment and Protects Islets From Cytokine-Induced Apoptosis
Diabetes,
September 1, 2007;
56(9):
2274 - 2283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Krebs, B. Brunmair, A. Brehm, M. Artwohl, J. Szendroedi, P. Nowotny, E. Roth, C. Furnsinn, M. Promintzer, C. Anderwald, et al.
The Mammalian Target of Rapamycin Pathway Regulates Nutrient-Sensitive Glucose Uptake in Man
Diabetes,
June 1, 2007;
56(6):
1600 - 1607.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Zhang, D. Su, S. Qu, T. Tse, R. Bottino, A.N. Balamurugan, J. Xu, J. S. Bromberg, and H. H. Dong
Sirolimus Is Associated With Reduced Islet Engraftment and Impaired {beta}-Cell Function
Diabetes,
September 1, 2006;
55(9):
2429 - 2436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Tancevski, A. Wehinger, W. Schgoer, P. Eller, S. Cuzzocrea, B. Foeger, J. R. Patsch, and A. Ritsch
Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice
FASEB J,
July 1, 2006;
20(9):
1328 - 1335.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Ryan, B. W. Paty, P. A. Senior, D. Bigam, E. Alfadhli, N. M. Kneteman, J. R.T. Lakey, and A.M. J. Shapiro
Five-Year Follow-Up After Clinical Islet Transplantation
Diabetes,
July 1, 2005;
54(7):
2060 - 2069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Chen, X. Li, and P. N. Epstein
MnSOD and Catalase Transgenes Demonstrate That Protection of Islets From Oxidative Stress Does Not Alter Cytokine Toxicity
Diabetes,
May 1, 2005;
54(5):
1437 - 1446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Hui, N. Khoury, X. Zhao, L. Balkir, E. D'Amico, A. Bullotta, E. D. Nguyen, A. Gambotto, and R. Perfetti
Adenovirus-Mediated XIAP Gene Transfer Reverses the Negative Effects of Immunosuppressive Drugs on Insulin Secretion and Cell Viability of Isolated Human Islets
Diabetes,
February 1, 2005;
54(2):
424 - 433.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Schroppel, N. Zhang, P. Chen, D. Chen, J. S. Bromberg, and B. Murphy
Role of Donor-Derived Monocyte Chemoattractant Protein-1 in Murine Islet Transplantation
J. Am. Soc. Nephrol.,
February 1, 2005;
16(2):
444 - 451.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Rickels, M. H. Schutta, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff
{beta}-Cell Function Following Human Islet Transplantation for Type 1 Diabetes
Diabetes,
January 1, 2005;
54(1):
100 - 106.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Larsen
Pancreas Transplantation: Indications and Consequences
Endocr. Rev.,
December 1, 2004;
25(6):
919 - 946.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Diabetes Association.
|
|
| |
|